Final announcement & program Joint EFSPI / BBS Webinar: Estimands addendum is final: Anything new for oncology?
Date: Monday, 29th June 2020, 09:00-11:45
Webinar: dial-in details will be communicated to registered participants
After the publication of the final version of the ICH E9 addendum, the BBS jointly with EFSPI would like to offer a half-day webinar on the broad topic of estimands in oncology drug development.
The event will feature talks from statisticians and clinicians in industry, regulatory agencies, and academia.
Initially, this event was planned as a full-day seminar on the Novartis campus. Given the current COVID-19 situation we turn this event into a series of webinars.
If you’d like to attend please fill out the registration form. After registration you will receive a calendar invite with a webex link.
The webinar is free of charge.
The organizing committee members are Evgeny Degtyarev, Kaspar Rufibach, Bibiana Blatna, Marie- Laure Casadebaig, Lynda Grinsted, Lorenzo Guizzaro, Wolfgang Kothny, Giusi Moffa, Hans-Jochen Weber. The event is supported by the European special interest group “Estimands in oncology”, sponsored by PSI and EFSPI, which is also an ASA scientific working group: http://www.oncoestimand.org.
********
Link to recording
Questions from the webinar chat addressed by the members of the organizing committee and panelists
Kaspar Rufibach, Roche, member of BBS board Welcome and scene setting
Anja Schiel, Norwegian Medicines Agency Experience with the estimand framework in oncology
Renaud Capdeville, Novartis Challenges and open questions in hematology: RATIFY
Tina Nielsen, Roche Challenges and open questions in hematology: GALLIUM
Hannes Buchner, Staburo & Ingolf Griebsch, Boehringer Ingelheim Treatment switching: challenges, estimands, and estimators
Stefan Englert, AbbVie Commentary on previous talks taking COVID-19 into account
Sorry, the comment form is closed at this time.